Degraders in epigenetic therapy: PROTACs and beyond.
Dai XJ, Ji SK, Fu MJ, Liu GZ, Liu HM, Wang SP, Shen L, Wang N, Herdewijn P, Zheng YC, Wang SQ, Chen XB.
Theranostics. 2024 Jan 27;14(4):1464-1499. doi: 10.7150/thno.92526. eCollection 2024.
PMID:38389844
The Ill Returning Traveler.
Rathjen NA, Shahbodaghi SD.
Am Fam Physician. 2023 Oct;108(4):396-403.
PMID:37843948
The future of general practitioner care in Lower Saxony, Germany: an analysis of actual vs target states using a GIS-based floating catchment area method.
Schoo J, Schüssler F.
Geospat Health. 2025 Jan 23;20(1). doi: 10.4081/gh.2025.1339. Epub 2025 Feb 19.
PMID:39973761
The burden of NAFLD (now referred to as MASLD)-related chronic liver disease and cirrhosis from 1990 to 2021 with projections to 2036: a comparative study of global China the United States and India.
Zeng J, Gu C, Wen C, Shen C.
Lipids Health Dis. 2025 Sep 29;24(1):298. doi: 10.1186/s12944-025-02750-z.
PMID:41024003
The burden, causes, and determinants of blindness and vision impairment in Asia: An analysis of the Global Burden of Disease Study.
Zou M, Chen A, Liu Z, Jin L, Zheng D, Congdon N, Jin G.
J Glob Health. 2024 Jun 14;14:04100. doi: 10.7189/jogh.14.04100.